<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01959451</url>
  </required_header>
  <id_info>
    <org_study_id>MucT001-13</org_study_id>
    <nct_id>NCT01959451</nct_id>
  </id_info>
  <brief_title>Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial</brief_title>
  <acronym>TROPICAL-ACS</acronym>
  <official_title>Platelet Function Guided Prasugrel Therapy in ACS Patients Undergoing PCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Klinikum der Universitaet Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Klinikum der Universitaet Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether a platelet function testing guided approach with a short-term
      (1 week) prasugrel treatment and a switch over to clopidogrel treatment in adequate
      responders to clopidogrel is non-inferior regarding the combined incidence of bleeding and
      thrombotic complications to a 12 month standard treatment with prasugrel in acute coronary
      syndrome (ACS) patients treated with percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients suffering of heart attack have highly activated blood platelets. During and after
      invasive treatment of blocked coronary vessels (percutaneous coronary intervention = PCI) a
      potent platelet inhibition is needed to reduce the risk of thrombotic complications which is
      particularly high within the first week after PCI. On the other hand, the use of potent
      platelet inhibitors such as prasugrel is associated with higher bleeding risk particularly
      when used at long-term. A combination of a potent antiplatelet drug (prasugrel) within the
      first week with a less potent antiplatelet drug (clopidogrel) thereafter might lead to a
      higher net clinical benefit - means less bleeding and thrombotic complications. This
      hypothesis is being investigated in the current trial.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2017</completion_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite of death from cardiovascular cause, myocardial infarction, stroke and bleeding grade ≥ 2 defined according to BARC criteria</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>bleeding events BARC class ≥2</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>economic impact of a platelet function testing guided tailored treatment for ACS patients</measure>
    <time_frame>12 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">2600</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>Prasugrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prasugrel 5 mg or 10mg daily for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prasugrel/Clopidogrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 0 - 7 Prasugrel 5 or 10mg Day 8 - 14 Clopidogrel 75mg q/d. On Day 14 platelet function testing Patients with HPR will be switched to Prasugrel the others will remain on Clopidogrel for 11 1/2 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prasugrel</intervention_name>
    <description>see Arm description</description>
    <arm_group_label>Prasugrel</arm_group_label>
    <other_name>Efient</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel</intervention_name>
    <description>see arm description</description>
    <arm_group_label>Prasugrel/Clopidogrel</arm_group_label>
    <other_name>Iscover</other_name>
    <other_name>Plavix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Troponin positive ACS

          -  Successful PCI (defined as a post PCI diameter stenosis &lt;20% and TIMI flow ≥2)

          -  A planned treatment of Prasugrel for 12 months after the procedure

          -  written informed consent

        Exclusion Criteria:

          -  Age &lt;18 years and &gt;80 years

          -  Subjects with known contraindications to Clopidogrel treatment, which are
             hypersensitivity to the drug substance or any component of the product and active
             pathological bleeding such as peptic ulcer or intracranial hemorrhage

          -  Subjects with known contraindications to Prasugrel treatment, which are
             hypersensitivity to the drug substance or any component of the product, active
             pathological bleeding such as peptic ulcer or intracranial hemorrhage and a history of
             prior transient ischemic attack (TIA) or stroke

          -  Cardiogenic shock

          -  Subjects requiring concomitant treatment with an anticoagulant agent (Vitamin-K
             antagonists or novel oral anticoagulants such as Rivaroxaban, Dabigatran or Apixaban)

          -  Indication for major surgery (per decision of the treating physician) for the planned
             duration of the study

          -  Simultaneous participation in another clinical trial or participation in any clinical
             trial involving administration of an investigational medicinal product within 30 days
             prior to clinical trial beginning

          -  Known or persistent abuse of medication, drugs or alcohol

          -  Current or planned pregnancy or nursing women, women 90 days after childbirth. Females
             of childbearing potential, who do not use and are not willing to use medically
             reliable methods of contraception for the entire study duration (such as oral,
             injectable, or implantable contraceptives, or intrauterine contraceptive devices)
             unless they are surgically sterilized / hysterectomized or there are any other
             criteria considered sufficiently reliable by the investigator in individual cases

          -  Evidence of significant active neuropsychiatric disease, in the investigator's opinion
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dirk Sibbing, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Julinda Mehilli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Munich University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Steffen Massberg, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Munich University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Medizin-Universität Graz, Univ. Klinik für Innere Medizin</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilhelminenspital Wien, 3. Medizinische Abteilung</name>
      <address>
        <city>Vienna</city>
        <zip>1160</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg, Department of Cardiology</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Bad Krozingen</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Stadtklinik Bad Tölz, Internal Medicine</name>
      <address>
        <city>Bad Tölz</city>
        <zip>83646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Josef Hospital, Katholisches Klinikum Bochum, Department of Cardiology</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Frankfurt, Department of Cardiology</name>
      <address>
        <city>Frankfurt</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Ostallgäu-Kaufbeuren, Klinik Füssen</name>
      <address>
        <city>Füssen</city>
        <zip>87629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center at the University Medical Center Goettingen</name>
      <address>
        <city>Goettingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Greifswald, Klinik u. Poliklinik für Innere Medizin B</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitäres Herzzentrum Hamburg, UKE</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Herzzentrum der Universität zu Köln</name>
      <address>
        <city>Köln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Mainz, Department of Cardiology</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Memmingen, Innere Medizin I</name>
      <address>
        <city>Memmingen</city>
        <zip>87700</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Munich University Hospital</name>
      <address>
        <city>Munich</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neuperlach, Department of Cardiology</name>
      <address>
        <city>Munich</city>
        <zip>81737</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bogenhausen, Department of Cardiology</name>
      <address>
        <city>Munich</city>
        <zip>81925</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg gGmbH, Herz-Kreislauf-Zentrum, Klinik für Kardiologie</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Rostock, Zentrum für Innere Medizin</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helios-Klinikum Siegburg, Abteilung für Kardiologie und Angiologie</name>
      <address>
        <city>Siegburg</city>
        <zip>53721</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital of Tuebingen, Department of Cardiology</name>
      <address>
        <city>Tuebingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Nordoberpfalz AG, Klinikum Weiden, Medizinische Klinik II</name>
      <address>
        <city>Weiden</city>
        <zip>92637</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis Egyetem Kardiovaszkuláris Centrum</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Budapest Military Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>1134</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Balatonfüred</name>
      <address>
        <city>Budapest</city>
        <zip>8230</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology Petz Aladár Megyei Oktató Kórház</name>
      <address>
        <city>Györ</city>
        <zip>9023</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Kecskemet</name>
      <address>
        <city>Kecskemet</city>
        <zip>6000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PTE KK Szívgyógyászati Klinika Intervenciós Kardiológia Részleg</name>
      <address>
        <city>Pecs</city>
        <zip>7624</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Heart Center Szeged</name>
      <address>
        <city>Szeged</city>
        <zip>6720</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>3rd Department of Cardiology, Upper Silesian Medical Centre, Medical University of Silesia, Katowice</name>
      <address>
        <city>Katowice</city>
        <zip>40635</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Department of Cardiology, Poznan University of Medical Science</name>
      <address>
        <city>Poznan</city>
        <zip>61848</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1st Department of Cardiology, Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>2097</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Interventional Cardiology and Angiology, Institute of Cardiology, Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>2795</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Poland</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/27652610</url>
    <description>Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial</description>
  </link>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2013</study_first_submitted>
  <study_first_submitted_qc>October 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 10, 2013</study_first_posted>
  <last_update_submitted>June 28, 2017</last_update_submitted>
  <last_update_submitted_qc>June 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Klinikum der Universitaet Muenchen</investigator_affiliation>
    <investigator_full_name>Dirk Sibbing</investigator_full_name>
    <investigator_title>Prof. Dr. Dirk Sibbing</investigator_title>
  </responsible_party>
  <keyword>Prasugrel</keyword>
  <keyword>Clopidogrel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticlopidine</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

